ABVX vs ALT: fair value comparison
ABIVAX Société Anonyme and Altimmune, Inc. · Updated 2026-10-19
ABVX reports in EUR, so no same-currency fair-value verdict is published for it. ALT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ABVX currently ranks higher by quality score.
| ABVX | ALT | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $95.10 | $2.20 |
| 12-month range | $72.50–$145.31 | $2.20–$6.18 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #215 of 301 Healthcare | #217 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Declining | Declining |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: ABVX fair value analysis · ALT fair value analysis